Cue Biopharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cue Biopharma and other ETFs, options, and stocks.

About CUE

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). 

CEO
Lucinda Warren
CEOLucinda Warren
Employees
29
Employees29
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
2014
Founded2014
Employees
29
Employees29

CUE Key Statistics

Market cap
42.65M
Market cap42.65M
Price-Earnings ratio
-1.51
Price-Earnings ratio-1.51
Dividend yield
Dividend yield
Average volume
38.75M
Average volume38.75M
High today
$0.4448
High today$0.4448
Low today
$0.36
Low today$0.36
Open price
$0.3832
Open price$0.3832
Volume
7.38M
Volume7.38M
52 Week high
$1.03
52 Week high$1.03
52 Week low
$0.1657
52 Week low$0.1657

Stock Snapshot

As of today, Cue Biopharma(CUE) shares are valued at $0.44. The company's market cap stands at 42.65M, with a P/E ratio of -1.51.

During the trading session on 2026-04-14, Cue Biopharma(CUE) shares reached a daily high of $0.44 and a low of $0.36. At a current price of $0.44, the stock is +22.0% higher than the low and still -1.3% under the high.

Trading volume for Cue Biopharma(CUE) stock has reached 7.38M, versus its average volume of 38.75M.

Over the past 52 weeks, Cue Biopharma(CUE) stock has traded between a high of $1.03 and a low of $0.17.

Over the past 52 weeks, Cue Biopharma(CUE) stock has traded between a high of $1.03 and a low of $0.17.

CUE News

TipRanks 1d
Cue Biopharma Shareholders Approve Reverse Stock Split Flexibility

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 7d
Cue Biopharma to receive $7.5M milestone payment from Boehringer Ingelheim pact

Cue Biopharma (CUE) announced that it will receive a $7.5M preclinical milestone payment under its collaboration and license agreement with Boehringer Ingelheim...

People also own

Based on the portfolios of people who own CUE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.